within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD25_MetforminSaxagliptinAndDapagliflozin;
model MetforminSaxagliptinAndDapagliflozin 
   extends Pharmacolibrary.Drugs.ATC.A.A10BD25;

  annotation(Documentation(
    info ="<html><body><p>Metformin, saxagliptin, and dapagliflozin is a fixed-dose combination oral medication used for the management of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent, saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Together, these drugs help improve glycemic control in adults with type 2 diabetes. This combination is approved for clinical use in various countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects based on published data for the individual components, as studies on the exact combination are not available.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end MetforminSaxagliptinAndDapagliflozin;
